AU2012358317B2 - Anti-cancer compounds targeting Ral GTPases and methods of using the same - Google Patents

Anti-cancer compounds targeting Ral GTPases and methods of using the same Download PDF

Info

Publication number
AU2012358317B2
AU2012358317B2 AU2012358317A AU2012358317A AU2012358317B2 AU 2012358317 B2 AU2012358317 B2 AU 2012358317B2 AU 2012358317 A AU2012358317 A AU 2012358317A AU 2012358317 A AU2012358317 A AU 2012358317A AU 2012358317 B2 AU2012358317 B2 AU 2012358317B2
Authority
AU
Australia
Prior art keywords
mmol
equ
ethanol
ral
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012358317A
Other languages
English (en)
Other versions
AU2012358317A1 (en
Inventor
Samy MEROUEH
Phillip REIGAN
David Ross
Martin A. Schwartz
Dan Theodorescu
Michael Fitzpatrick Wempe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
UVA Licensing and Ventures Group
Indiana University Research and Technology Corp
Original Assignee
University of Colorado Boulder
Indiana University Research and Technology Corp
University of Virginia Patent Foundation
University of Colorado System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Boulder, Indiana University Research and Technology Corp, University of Virginia Patent Foundation, University of Colorado System filed Critical University of Colorado Boulder
Publication of AU2012358317A1 publication Critical patent/AU2012358317A1/en
Assigned to INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, THE REGENTS OF THE UNIVERSITY OF COLORADO, UNIVERSITY OF VIRGINIA PATENT FOUNDATION reassignment INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION Amend patent request/document other than specification (104) Assignors: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, THE REGENTS OF THE UNIVERSITY OF COLORADO, THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Application granted granted Critical
Publication of AU2012358317B2 publication Critical patent/AU2012358317B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012358317A 2011-12-21 2012-12-21 Anti-cancer compounds targeting Ral GTPases and methods of using the same Ceased AU2012358317B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578869P 2011-12-21 2011-12-21
US61/578,869 2011-12-21
PCT/US2012/071341 WO2013096820A1 (en) 2011-12-21 2012-12-21 Anti-cancer compounds targeting ral gtpases and methods of using the same

Publications (2)

Publication Number Publication Date
AU2012358317A1 AU2012358317A1 (en) 2014-07-17
AU2012358317B2 true AU2012358317B2 (en) 2017-12-14

Family

ID=48669550

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012358317A Ceased AU2012358317B2 (en) 2011-12-21 2012-12-21 Anti-cancer compounds targeting Ral GTPases and methods of using the same

Country Status (8)

Country Link
US (3) US9353121B2 (OSRAM)
EP (1) EP2793881B1 (OSRAM)
JP (1) JP6473330B2 (OSRAM)
KR (1) KR102097343B1 (OSRAM)
CN (1) CN104271132B (OSRAM)
AU (1) AU2012358317B2 (OSRAM)
CA (1) CA2859985C (OSRAM)
WO (1) WO2013096820A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104271132B (zh) 2011-12-21 2018-01-12 科罗拉多大学董事会法人团体 靶向Ral GTP酶的抗癌化合物及使用其的方法
EP3166609B1 (en) * 2014-07-10 2020-03-11 The Regents of The University of Colorado, A Body Corporate 6-amino-1,3-dimethyl-4-(4-(trifluoromethyl)phenyl)-1,4-dihydropyrano [2,3-c]pyrazole-5-carbonitrile and related compounds as ral gtpase inhibitors for treating cancer metastasis
SI3447050T1 (sl) 2014-09-19 2020-08-31 Forma Therapeutics, Inc. Derivati piridin-2(1H)-on kinolinona kot inhibitorji mutirane izocitratne dehidrogenaze
CA2961793C (en) 2014-09-19 2021-03-16 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
US10934291B2 (en) 2014-09-25 2021-03-02 Duke University Kinase inhibitors and related methods of use
US10646475B2 (en) * 2015-03-10 2020-05-12 The Trustees Of Princeton University SHMT inhibitors
WO2016205460A1 (en) * 2015-06-16 2016-12-22 Nantbioscience, Inc. Polycyclic derivatives targeting ral gtpases and their therapeutical applications
GEP20207167B (en) 2016-06-22 2020-10-12 Univ Vanderbilt Positive allosteric modulators of the muscarinic acetylcholine receptor m4
US10077273B2 (en) 2016-09-14 2018-09-18 The Trustees Of Princeton University SHMT inhibitors
KR102507847B1 (ko) 2016-10-28 2023-03-08 서울대학교병원 페닐 프탈라진 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
CN109863139B (zh) 2016-11-07 2023-02-17 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
CN109862893B (zh) 2016-11-07 2023-02-17 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
US11008335B2 (en) 2016-11-07 2021-05-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
CN112397076A (zh) 2016-11-23 2021-02-23 瑞典爱立信有限公司 用于自适应控制去相关滤波器的方法和装置
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
MA51036A (fr) 2017-12-05 2021-03-17 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
WO2019142191A1 (en) * 2018-01-17 2019-07-25 Gavish-Galilee Bio Applications Ltd. New methionine metabolic pathway inhibitors
BR112020014559A2 (pt) 2018-01-17 2020-12-08 Migal - Galilee Research Institute Ltd. Inibidores inovadores da via metabólica da metionina
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US10532047B2 (en) 2018-05-16 2020-01-14 Forma Therapeutics, Inc. Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11576906B2 (en) 2018-05-16 2023-02-14 Forma Therapeutics, Inc. Inhibiting mutant IDH-1
CN109305972B (zh) * 2018-09-27 2021-07-09 广州医科大学 一种二氢吡喃并吡唑类化合物及其制备方法和应用
CN109734676B (zh) * 2019-01-16 2021-01-29 四川大学 苯并二氮杂卓类衍生物及其制备方法和应用
EP4076416A4 (en) * 2019-12-19 2024-04-10 The Trustees of Indiana University Small-molecule covalent inhibition of ral gtpases
CN111406752B (zh) * 2020-04-23 2021-07-23 中国农业科学院植物保护研究所 二氢吡咯并吡唑酮类衍生物作为几丁质酶抑制剂或杀线虫剂的应用
US20230293490A1 (en) * 2020-08-17 2023-09-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Profilin1:actin inhibitor as an anti-angiogenic compound
US20230414610A1 (en) * 2020-11-18 2023-12-28 Texas Tech University System Therapies for cancer using small molecules that bind to and inhibit rail interacting proteins
US20240325374A1 (en) * 2021-07-23 2024-10-03 The Research Institute At Nationwide Children's Hospital Inhibiting intracellular pathogens
US20250134888A1 (en) * 2022-02-07 2025-05-01 Cornell University Inhibitors of malic enzyme 1
CN120168481B (zh) * 2025-05-14 2025-08-19 天津医科大学 一种抑制REXO4消解R-loop酶活性的小分子及其在制备肿瘤药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US362503A (en) * 1887-05-10 Sectional boat
US361185A (en) * 1887-04-12 Poueths to john h
US4555396A (en) 1982-12-22 1985-11-26 Eastman Kodak Company Use of pyrylium and thiapyrylium compounds as biological stains
US5750550A (en) * 1995-09-15 1998-05-12 Sanofi 2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3 (2H)-One 1, 1-dioxides and compositions and method of use thereof
JPH10279480A (ja) * 1997-04-07 1998-10-20 Mitsubishi Chem Corp 皮膚組織障害の予防・治療剤
US6143471A (en) * 1998-03-10 2000-11-07 Mitsubishi Paper Mills Limited Positive type photosensitive composition
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
US20070105105A1 (en) 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
CA2533803A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
WO2006126625A1 (ja) * 2005-05-25 2006-11-30 Mitsubishi Tanabe Pharma Corporation ピラゾロン誘導体を含む医薬
EP1920048A4 (en) * 2005-07-29 2009-12-09 Childrens Hosp Medical Center GTASE INHIBITORS AND USE METHOD AND CRYSTAL STRUCTURE OF RAC-1 GTASE
KR20080040032A (ko) 2005-09-02 2008-05-07 티보텍 파마슈티칼즈 리미티드 Ｈｃｖ 저해제로서의 벤조디아제핀
EP1957474A4 (en) 2005-11-04 2011-08-24 Harvard College SYNTHESIS OF FTSZ HEMMERN
WO2007081966A2 (en) 2006-01-09 2007-07-19 University Of Southern California Small molecules for treating cancer and abnormal cell proliferation disorders
WO2008143894A2 (en) 2007-05-14 2008-11-27 Dana-Farber Cancer Institute, Inc. Phosphorylated rala
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011010715A1 (ja) 2009-07-24 2011-01-27 国立大学法人 東京大学 Ｐr－Ｓｅｔ７阻害剤
WO2011035143A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Methods and compositions for inhibiting rho-mediated diseases and conditions
US8673913B2 (en) 2009-11-13 2014-03-18 Case Western Reserve University SHP-2 phosphatase inhibitor
US20120214824A1 (en) 2010-12-08 2012-08-23 Bradley Tait Proteostasis regulators
CN104271132B (zh) 2011-12-21 2018-01-12 科罗拉多大学董事会法人团体 靶向Ral GTP酶的抗癌化合物及使用其的方法
WO2013096852A1 (en) 2011-12-21 2013-06-27 The Regents Of The University Of Colorado Biomarkers of cancer
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
EP2858981A1 (en) 2012-06-06 2015-04-15 Basf Se Pyrazolopyrans having herbicidal and pharmaceutical properties
CN103910737B (zh) 2014-03-25 2016-08-17 浙江师范大学 手性的1,4-二氢吡喃(2,3-c)吡唑衍生物及其合成方法和应用

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ABDELRAZEK, F. M. et. al. Arch. Pharm. Chem. Life. Sci., 2006, 339, 305-312 *
AL-MATAR, H. M. et. al. MOLECULES, 2010, 15, 6619 -6629 *
Database Registry Chemical Abstracts Service, Columbus, Ohio, Accession No. RN 168429-49-0, Entered STN: 05 Oct 1995 *
Database Registry Chemical Abstracts Service, Columbus, Ohio, Accession No. RN 53316-58-8, Entered STN: 16 Nov 1984 *
HAFIZ, I. S. a. et. al. J. Chem. Research (S). 1998, 690-691 *
HAMAD, N. M. et. al., GENES & DEVELOPMENT, 2002,16, 2045-2057 *
LIM, K-H., et. al., CANCER CELL, 2005, , 533 - 545 *
SMITH, S. C. et. al., CANCER RESEARCH, 2006, 66(4), 1917 - 1922 *

Also Published As

Publication number Publication date
EP2793881B1 (en) 2018-10-31
US11964985B2 (en) 2024-04-23
US20160280715A1 (en) 2016-09-29
CA2859985A1 (en) 2013-06-27
EP2793881A1 (en) 2014-10-29
CN104271132A (zh) 2015-01-07
CN104271132B (zh) 2018-01-12
KR20150010696A (ko) 2015-01-28
AU2012358317A1 (en) 2014-07-17
US9353121B2 (en) 2016-05-31
JP2015503507A (ja) 2015-02-02
WO2013096820A1 (en) 2013-06-27
CA2859985C (en) 2020-11-03
JP6473330B2 (ja) 2019-02-20
EP2793881A4 (en) 2015-05-20
US10689392B2 (en) 2020-06-23
US20140315894A1 (en) 2014-10-23
KR102097343B1 (ko) 2020-04-07
US20200270263A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
AU2012358317B2 (en) Anti-cancer compounds targeting Ral GTPases and methods of using the same
US10676480B2 (en) Anti-cancer compounds targeting Ral GTPases and methods of using the same
US9938245B2 (en) Carbonyl erastin analogs and their use
RS53831B1 (sr) Pirazolohinolin derivati kao inhibitori dnk-pk

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired